In the claims:

Claims 1-14 - Cancelled

15. (Currently amended) ~~The use of~~ A pharmaceutical composition comprising at least one compound ~~compounds~~ of the formula (I)



(I)

in which

Ar is an aromatic or heteroaromatic ring system having a single ring;

X^1 is NR^3R^4, OR^3, SR^3, $COOR^3$, $CONR^3R^4$ or COR^5,

where

R^3 is H or a group of the formula II, IIIa, IIIb or IIIc:



(II)



(IIIa)



(IIIb)



(IIIc)

where

X^2 is NH, NR^4, O or S,

X^3 is NH, NR^4, O, S, CO, COO, CONH OR $CONR^4$,

Y is $C(R^8)_2$,

R^4 is H or an alkyl, alkenyl or alkynyl radical,

R^7 is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical or -SO_2-R^9,

R^8 is in each case independently H, halogen or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical,

R^9 is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical and

n is an integer from 0 to 2,

~~R^4 is as defined above,~~

R^5 is H, an alkyl, alkenyl, alkynyl, carboxyalkyl, carboxyalkenyl, carboxyalkynyl, carboxyaryl or carboxyheteroaryl radical;

R^2 is halogen, $C(R^6)_3$, $C_2(R^6)_5$, $OC(R^6)_3$ or $OC^2(R^6)_5$,

where

R^6 is in each case independently H or halogen~~, in particular F~~; and

m is an integer from 0 to 4;

or salts of said at least one compound ~~for preparing an agent for inhibition of the urokinase plasminogen activator~~, and

a pharmaceutically acceptable carrier therefor.

16. (Currently amended) ~~The use as claimed in~~ A pharmaceutical composition according to claim 15, in which Ar is a benzene ring.

17. (Currently amended) ~~The use as claimed in~~ A pharmaceutical composition according to claim 16, in which the substituents -CH_2X^1 and -$NHC(NH)NH_2$ are arranged in a para position to each other.

18. (Currently amended) ~~The use as claimed in~~ A pharmaceutical composition according to claim 15, in which R^7 and R^9 are ~~selected from the group comprising~~ at least one aryl~~, in particular phenyl radicals and~~ , at least one tertiary alkyl radical ~~radicals and~~ or at least one cycloalkyl radical ~~radicals, in particular bicycloalkyl radicals~~

~~such as adamanty~~.

19. (Currently amended) ~~The use of~~ A pharmaceutical composition comprising at least one compound ~~compounds~~ of the formula (IV)



in which

X^1 is in each case independently NR^3R^4, OR^3, SR^3, $COOR^3$, $CONR^3R^4$ or COR^5, ~~with the proviso that the two arylguanidine groups are linked to one another via the substituents CH_2X^1,~~

where

R^3 is in each case independently H or any organic radical,

R^4 is in each case independently H or an alkyl, alkenyl or alkynyl radical;

Ar is in each case independently an aromatic or heteroaromatic ring system,

R^2 is in each case independently halogen, $C(R^6)_3{}^3$, $C_2(R^6)_5$, $OC(R^6)_3$ or $OC_2(R^6)_5$,

where

R^6 is in each case independently H or halogen ~~in particular F~~; and

m is an integer from 0 to 4;

or salts of said at least one compound ~~compounds for preparing an agent for inhibition of the urokinase plasminogen activator~~ , and

a pharmaceutically acceptable carrier therefor.

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Currently amended) ~~The use as claimed in~~ A pharmaceutical composition according to claim 15 ~~for preparing~~ wherein said composition is adapted to be administered orally, topically, rectally or parenterally ~~administrable medicaments~~.

24. (Currently amended) ~~The use as claimed in~~ A pharmaceutical composition according to claim 15 wherein said composition is adapted to be administered in the form of tablets, coated tablets, capsules, pellets, suppositories, solutions or transdermal systems ~~such as plasters~~.

25. (Currently amended) A method for controlling pathological overexpression of urokinase or/and urokinase receptor in a patient in need of such control comprising administering to the patient a pharmaceutical composition according to claim 15 in a overexpression of urokinase or/and urokinase receptor controlling effective amount ~~inhibiting urokinase in living creatures, in particular in humans, by administering an effective quantity of at least one compound as claimed in claim 15~~.

26. (Canceled)

27. (New) A method for controlling the formation of metastases in a patient in need of such control comprising administering to a patient a pharmaceutical composition according to claim 15 in a formation of metastases controlling effective amount.

28. (New) A pharmaceutical kit comprising the following components:

(a) at least one first anti-tumor agent of the formula (I)



(I)

in which

Ar is an aromatic or heteroaromatic ring system having a single ring;

X^1 is NR^3R^4, OR^3, SR^3, $COOR^3$ $CONR^3R^4$ or COR^5,

where

R^3 is H or a group of the formula II, IIIa, IIIb or IIIc:



(II)



(IIIa)



(IIIb)



(IIIc)

B3

where

X^2 is NH, NR^4, O or S,

X^3 is NH, NR^4, O, S, CO, COO, CONH OR $CONR^4$,

Y is $C(R^8)_2$,

R^4 is H or an alkyl, alkenyl or alkynyl radical,

R^7 is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical or -SO_2-R^9,

R^8 is in each case independently H, halogen or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical,

R^9 is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical and

n is an integer from 0 to 2,

R^5 is H, an alkyl, alkenyl, alkynyl, carboxyalkyl, carboxyalkenyl, carboxyalkynyl, carboxyaryl or carboxyheteroaryl radical;

R^2 is halogen, $C(R^6)_3$, $C_2(R^6)_5$, $OC(R^6)_3$ or $OC^2(R^6)_5$,

where

R^6 is in each case independently H or halogen; and

m is an integer from 0 to 4;

or salts of said at least one compound, and

(b) a second anti-tumor agent,

wherein said first anti-tumor agent and said second anti-tumor agent are in separate containers.

29. (New) A kit according to claim 28, wherein R^6 in said compound of formula is F.

30. (New) A pharmaceutical composition according to claim 15, wherein said

compound of the formula I has a K_i that is at least two times lower for uPA than for tPA.

31. (New) A pharmaceutical composition according to claim 15, wherein said compound of the formula I has a K_i that is at least five times lower for uPA than for tPA.

32. (New) A pharmaceutical composition according to claim 15, wherein said compound of the formula I has a K_i that is at least 10 times lower for uPA than for tPA.

33. (New) A pharmaceutical composition according to claim 15, wherein said compound of the formula I has a K_i that is at least 1000 times lower for uPA than for tPA.

34. (New) A pharmaceutical composition according to claim 15, wherein said compound of the formula I is conjugated with at least one physiological effective substance, wherein said substance is at least one radiolabelled substance.

35. (New) A kit according to claim 28, wherein said second anti-tumor agent is cisplatin, 5-fluorouracil or a peptide.

36. (New) A pharmaceutical composition according to claim 15, wherein said compound of the formula I is incorporated into a carrier vesicle.

37. (New) A pharmaceutical composition according to claim 15, wherein R^6 in said compound of formula I is F.

38. (New) A pharmaceutical composition according to claim 18, wherein said at least one aryl radical is a phenyl radical.

B3

39. (New) A pharmaceutical composition according to claim 18, wherein said at least one cycloalkyl radical is a bicycloalkyl radical.

40. (New) A pharmaceutical composition according to claim 39, wherein said bicycloalkyl radical is an adamantyl radical.

41. (New) A pharmaceutical composition according to claim 19, wherein R^6 in said compound of formula I is F.

42. (New) A method for treating tumors in a patient in need of such treatment comprising administering to a patient a pharmaceutical composition according to claim 15 in a tumor treating effective amount.

43 . (New) A compound of the formula (I)



(I)

in which

Ar is an aromatic or heteroaromatic ring system having a single ring;

X^1 is NR^3R^4, OR^3, SR^3, $COOR^3$, $CONR^3R^4$ or COR^5,

where

R^3 is H or a group of the formula II, IIIa, IIIb or IIIc:



where

X^2 is NH, NR^4, O or S,

X^3 is NH, NR^4, O, S, CO, COO, CONH OR $CONR^4$,

Y is $C(R^8)_2$,

R^4 is H or an alkyl, alkenyl or alkynyl radical,

R^7 is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical or -SO_2-R^9,

R^8 is in each case independently H, halogen or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical,

B3

R^9 is H or an alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical and

n is an integer from 0 to 2,

R^5 is H, an alkyl, alkenyl, alkynyl, carboxyalkyl, carboxyalkenyl, carboxyalkynyl, carboxyaryl or carboxyheteroaryl radical;

R^2 is halogen, $C(R^6)_3$, $C_2(R^6)_5$, $OC(R^6)_3$ or $OC^2(R^6)_5$,

where

R^6 is in each case independently H or halogen; and

m is an integer from 0 to 4, with the provisos that

when Ar=phenyl, m=O, CH_2X^1 is not CH_3COOH_2,

when Ar=phenyl, m=0, $X^1=NR^3R^4$ with R^4=H and R^3= -C00R^7 with R^7=tertbutyl and m=0, the compound of formula (I) is not in the hydrochloride salt form, and

when Ar=phenyl, m=0 and $X^1=NH_2$ the compound of formula (I) is not in the bistrifluoroacetate salt form.

44. (New) The compound of claim 43, in which Ar is a benzene ring.

45. (New) The compound of claim 44, in which the substituents -CH_2X^1 and -$NHC(NH)NH_2$ are arranged in a para position to each other.

46. (New) The compound of claim 43, in which R^7 and R^9 are at least one aryl radical, at least one tertiary alkyl radical or at least one cycloalkyl radical.

47. (New) A compound according to claim 46, wherein said at least one aryl radical is a phenyl radical.

48. (New) A compound according to claim 46, wherein said at least one cycloalkyl radical is a bicycloalkyl radical.

B3

49. (New) A compound according to claim 48, wherein said bicycloalkyl radical is an adamantyl radical.

50. (New) A compound according to claim 43 wherein R^6 in said compound of formula I is F.

51. (New) A method for inhibiting a urokinase plasminogen activator in a patient in need of such inhibition comprising administering to said patient a compound according to claim 43 in a urokinase plasminogen activator inhibiting effective amount.

52. (New) The method of claim 51, wherein Ar is a benzene ring.

53. (New) The method of claim 52, in which the substituents $-CH_2X^1$ and $-NHC(NH)NH_2$ are arranged in a para position to each other.

54. (New) The method of claim 51, in which R^7 and R^9 are at least one aryl, at least one tertiary alkyl radical or at least one cycloalkyl radical.

55. (New) The method of claim 54, in which R^7 and R^9 are phenyl radicals.

56. (New) The method of claim 54, in which R^7 and R^9 are bicyloalkyl radicals.

57. (New) The method of claim 54, in which R^7 and R^9 are adamantyl.

58. (New) A method according to claim 51, wherein 0.01 to 100 mg of said compound is administered per kg of body weight per day.

59. (New) A method according to claim 58, wherein 0.1 to 100 mg of said compound

is administered per kg of body weight per day.

60. (New) A method according to claim 51, wherein R^6 in said compound of formula I is F.

61 . (New) A method for controlling disorders which are related to a pathological overexpression of urokinase plasminogen activator in a patient in need of such inhibition comprising administering to said patient at least one compound according to claim 43 in a pathological overexpression of urokinase plasminogen activator inhibiting effective amount.

62. (New) The method of claim 61, in which Ar is a benzene ring.

63. (New) The method of claim 62, in which the substituents $-CH_2X^1$ and $-NHC(NH)NH_2$ are arranged in a para position to each other.

64. (New) The method of claim 61, in which R^7 and R^9 are at least one aryl radical, at least one tertiary alkyl radical or at least one cycloalkyl radical.

65. (New) The method of claim 64, in which R^7 and R^9 are phenyl radicals.

66. (New) The method of claim 64, in which R^7 and R^9 are bicyloalkyl radicals.

67. (New) The method of claim 64, in which R^7 and R^9 are adamantyl.

68. (New) A method according to claim 61, wherein R^6 in said compound of formula I is F.

69. (New) A method for controlling tumors in a patient in need of such control comprising administering to said patient at least one compound according to claim 43 is administered in a tumor controlling effective amount.

70. (New) The method of claim 69, wherein Ar is a benzene ring.

71. (New) The method of claim 70, in which the substituents $-CH_2X^1$ and $-NHC(NH)NH_2$ are arranged in a para position to each other.

72. (New) The method of claim 69, in which R^7 and R^9 are at least one aryl , at least one tertiary alkyl radical or at least one cycloalkyl radical.

73. (New) The method of claim 72, in which R^7 and R^9 are phenyl radicals.

74. (New) The method of claim 72, in which R^7 and R^9 are bicyloalkyl radicals.

75. (New) The method of claim 72, in which R^7 and R^9 are adamantyl.

76. (New) A method according to claim 69, wherein R^6 in said compound of formula I is F.

77. (New) A method for controlling the formation of metastasis in a patient in need of such control comprising administering to said patient at least one compound according to claim 43 in a formation of metastases controlling effective amount.

78. (New) The method of claim 77, wherein Ar is a benzene ring.

79. (New) The method of claim 78, in which the substituents $-CH_2X^1$ and -

$NHC(NH)NH_2$ are arranged in a para position to each other.

80. (New) The method of claim 77, in which R^7 and R^9 are at least one aryl , at least one tertiary alkyl radical or at least one cycloalkyl radical.

81. (New) The method of claim 80, in which R^7 and R^9 are phenyl radicals.

82. (New) The method of claim 80, in which R^7 and R^9 are bicyloalkyl radicals.

83. (New) The method of claim 82, in which R^7 and R^9 are adamantyl.

84. (New) A compound of the formula (IV)



in which

X^1 is in each case independently NR^3R^4, OR^3, SR^3, $COOR^3$, $CONR^3R^4$ or COR^5, where

R^3 is in each case independently H or any organic radical,

R^4 is in each case independently H or an alkyl, alkenyl or alkynyl radical;

Ar is in each case independently an aromatic or heteroaromatic ring system,

R^2 is in each case independently halogen, $C(R^6)_3{}^3$, $C_2(R^6)_5$, $OC(R^6)_3$ or $OC_2(R^6)_5$, where

R^6 is in each case independently H or halogen; and

m is an integer from 0 to 4;

or salts of said compound.

85. (New) A method for inhibiting urokinase plasminogen activator in a patient in need of such inhibition comprising administering to said patient at least one compound according to claim 84.

86. (New) A method for controlling pathological overexpression of urokinase or/and urokinase receptor in a patient in need of such control comprising administering to said patient a pharmaceutical composition according to claim 19 in a overexpression of urokonase or/and urikinase receptor controlling effective amount.

87. (New) A method for controlling the formation of metastases in a patient in need of such control comprising administering to said patient a pharmaceutical composition according to claim 19 in a formation of metastases controlling effective amount.

88. (New) A method for treating tumors in a patient in need of such treatment comprising administering to said patient a pharmaceutical composition according to claim 19 in a tumor treating effective amount.